AVR 118

Drug Profile

AVR 118

Alternative Names: AVR-118; AVR123; OHR-118; OHR/AVR 118; Peptide R; Product R; Reticulose; Substance R

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Advanced Viral Research
  • Developer Advanced Viral Research; McGill University; Ohr Pharmaceutical
  • Class Antineoplastics; Antirheumatics; Antivirals; Peptide nucleic acids
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anorexia; Cachexia; Cancer; Haematological malignancies; HIV infections; Human papillomavirus infections; Multiple sclerosis; Rheumatoid arthritis; Type 2 diabetes mellitus; Wounds

Most Recent Events

  • 10 Nov 2016 Discontinued - Phase-II for Anorexia (In the elderly, In adults) in Canada before November 2016 (SC)
  • 21 Mar 2013 Efficacy and adverse events data from a phase II trial in Cachexia released by Ohr Pharmaceuticals
  • 21 Mar 2013 Ohr Pharmaceuticals completes a phase II trial in Cachexia in Canada (NCT01206335)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top